Home > Riviste > The Journal of Cardiovascular Surgery > Fascicoli precedenti > The Journal of Cardiovascular Surgery 2013 April;54(2) > The Journal of Cardiovascular Surgery 2013 April;54(2):161-71

ULTIMO FASCICOLO
 

ARTICLE TOOLS

Estratti

THE JOURNAL OF CARDIOVASCULAR SURGERY

Rivista di Chirurgia Cardiaca, Vascolare e Toracica


Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 2,179


eTOC

 

  INNOVATIVE TECHNOLOGIES IN AORTIC ENDOGRAFTING


The Journal of Cardiovascular Surgery 2013 April;54(2):161-71

Copyright © 2013 EDIZIONI MINERVA MEDICA

lingua: Inglese

Experience with early TEVAR treatment of uncomplicated type B aortic dissection

Lin J. 1, 2, Marrocco C. 1, Galovich J. 1, Kopchok G. 1, Khoynezhad A. 1, 2, 3, Walot I. 4, Haji F. 1, Jaber R. 1, Donayre C. 1, White R. 1

1 Division of Vascular Surgery, Harbor-UCLA Medical Center, Torrance, CA, USA; 2 Division of Cardiothoracic Surgery, Harbor-UCLA Medical Center, Torrance, CA, USA; 3 Division of Cardiothoracic Surgery, Cedars-Sinai Medical Center, Los Angeles, CA, USA; 4 Department of Radiology, Harbor-UCLA Medical Center, Torrance, CA, USA


PDF  


The current paradigm for the treatment of chronic type B aortic dissection involves primarily medical treatment. The patients are then followed for sequelae like progressive dissection or aneurysmal degeneration, selecting this subgroup for further intervention. The European Collaborator Registry, the Talent Thoracic Retrospective Registry, and several meta-analysis showed that the uncomplicated type B dissection patients who underwent thoracic endovascular aortic repair (TEVAR) outperformed their counterpart in the complicated group. The INSTEAD trial, the first randomized trial to examine whether TEVAR is better than medical management in the chronic stable dissection patients, showed no benefit early on although mid-term data might show some benefit. Clearly more randomized controlled trials are necessary to create a paradigm shift. In the United States, the FDA approved TEVAR devices are for the descending thoracic aortic aneurysm and transection only. The use of these devices for dissection is off-label or for investigation only. As future study might broaden the use of TEVAR for the chronic dissection patients, the use of TEVAR in hybrid surgery and in the ascending aorta is also broadening the indication for this technology. With two decades of innovation behind, TEVAR will continue to evolve and innovate in the years ahead.

inizio pagina

Publication History

Per citare questo articolo

Corresponding author e-mail

linj2011@gmail.com